Observes eptinezumab for migraine in everyday real-life care
Studies how eptinezumab works and is tolerated in adults with migraine.
Plain-language title generated from the registry record
Registry title: EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
Key facts
- Where
- Roma, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05570149, who can take part
Where in Italy
- IRCCS San Raffaele RomaRoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele Roma
- Trial code
- NCT05570149
- Record updated
- 1 May 2025
- Original description
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.Read full original descriptionShow less
EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Inclusion: Age between 18 and 75 years; Males and females; Willingness to sign the informed consent; High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months; Chronic migraine, according to the ICHD-III criteria.
Exclusion: Current treatment with other mAbs; Vascular disease or Raynaud; Other headaches different than migraine; Known intolerance to eptinezumab or eccipients.